3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Metabolic Syndrome
1
Lymphoma, Non-Hodgkin
1
Heart Failure
1
Dyslipidemias
1
Central Nervous System Neoplasms
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Cardiomyopathies
1
Interventions
Echocardiography
14
Doxorubicin
10
Exercise
9
Electrocardiography
7
Trastuzumab
6
Cyclophosphamide
5
Carvedilol
5
Docetaxel
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Magnetic Resonance Spectroscopy
2
Ivabradine
2
High-Intensity Interval Training
2
Exercise Test
2
Chemoradiotherapy
2
Blood Specimen Collection
2
Bisoprolol
2
Antineoplastic Agents
2
Anthracyclines
2
sulforaphane
1
schizandrin
1
pegfilgrastim
1
nicotinamide-beta-riboside
1
mitoquinone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cardiotoxicity
×
Pulse Wave Analysis
×
Clear all
NCT07041827
2025-06-27
CLARITY
The Netherlands Cancer Institute
Completed
217 enrolled